These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2530072)

  • 1. Naka-Rushton equation parameters in electroretinogram analysis of daunomycin effects on retinal function.
    Gangadhar DV; Wolf BM; Tanenbaum HL
    Doc Ophthalmol; 1989 May; 72(1):61-70. PubMed ID: 2530072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular toxicity of daunomycin: effects of subdivided doses on the rabbit retina after vitreous gas compression.
    Steinhorst UH; Hatchell DL; Chen EP; Machemer R
    Graefes Arch Clin Exp Ophthalmol; 1993 Oct; 231(10):591-4. PubMed ID: 8224935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daunomycin in the treatment of experimental proliferative vitreoretinopathy: retinal toxicity of intravitreal daunomycin in the rabbit.
    Santana M; Wiedemann P; Kirmani M; Minckler DS; Patterson R; Sorgente N; Ryan SJ
    Graefes Arch Clin Exp Ophthalmol; 1984; 221(5):210-3. PubMed ID: 6489768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of intravitreally injected ciprofloxacin in phakic rabbit eyes.
    Kim SH; Kim JH; Cho KS; Kwak JS
    Korean J Ophthalmol; 1995 Jun; 9(1):12-8. PubMed ID: 7674548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The luminance-response function of the dark-adapted rabbit electroretinogram.
    Chung KH; Kim SH; Cho JH
    Korean J Ophthalmol; 1994 Jun; 8(1):1-5. PubMed ID: 7933627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of experimental massive periretinal proliferation by daunomycin: dose-response relation.
    Wiedemann P; Kirmani M; Santana M; Sorgente N; Ryan SJ
    Graefes Arch Clin Exp Ophthalmol; 1983; 220(5):233-5. PubMed ID: 6629017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aclacinomycin A in the treatment of experimental proliferative vitreoretinopathy. Efficacy and toxicity in the rabbit eye.
    Steinhorst UH; Chen EP; Hatchell DL; Samsa GP; Saloupis PT; Westendorf J; Machemer R
    Invest Ophthalmol Vis Sci; 1993 Apr; 34(5):1753-60. PubMed ID: 8473115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiproliferative drugs in the treatment of experimental proliferative vitreoretinopathy.
    Kirmani M; Santana M; Sorgente N; Wiedemann P; Ryan SJ
    Retina; 1983; 3(4):269-72. PubMed ID: 6201971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoposide as a virocidal anticytomegalovirus therapy: intravitreal toxicology and pharmacology in rabbits.
    Morlet N; Stayt J; Vaegan ; Salonikas C; Naidoo D; Crouch R; Graham G; Coroneo M
    Aust N Z J Ophthalmol; 1999 Oct; 27(5):342-9. PubMed ID: 10571395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of vitreous clearance and potential retinal toxicity of intravitreal lornoxicam (xefo).
    Diakonis VF; Tsourdou A; Tzatzarakis MN; Tsika C; Charisis S; Naoumidi I; Plainis S; Tsilimbaris MK
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):627-32. PubMed ID: 23556534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinal function and histologic changes following intravitreal injection of indocyanine green in a rabbit model.
    Chao AN; Chen SN; Kuo YH
    J Ocul Pharmacol Ther; 2004 Oct; 20(5):450-9. PubMed ID: 15650520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
    Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
    Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of three methods of estimating the parameters of the Naka-Rushton equation.
    Evans LS; Peachey NS; Marchese AL
    Doc Ophthalmol; 1993; 84(1):19-30. PubMed ID: 8223107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages.
    Hui YN; Liang HC; Cai YS; Kirchhof B; Heimann K
    Graefes Arch Clin Exp Ophthalmol; 1993 Feb; 231(2):109-14. PubMed ID: 8444357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N,N-dimethyladriamycin for treatment of experimental proliferative vitreoretinopathy: efficacy and toxicity on the rabbit retina.
    Steinhorst UH; Chen EP; Machemer R; Hatchell DL
    Exp Eye Res; 1993 Apr; 56(4):489-95. PubMed ID: 8500561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Full-field electroretinogram in autism spectrum disorder.
    Constable PA; Gaigg SB; Bowler DM; Jägle H; Thompson DA
    Doc Ophthalmol; 2016 Apr; 132(2):83-99. PubMed ID: 26868825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes.
    Hrach CJ; Johnson MW; Hassan AS; Lei B; Sieving PA; Elner VM
    Arch Ophthalmol; 2000 May; 118(5):659-63. PubMed ID: 10815158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraocular toxicity and pharmacokinetics of candesartan in a rabbit model.
    Lee JE; Lim DW; Park HJ; Shin JH; Lee SM; Oum BS
    Invest Ophthalmol Vis Sci; 2011 May; 52(6):2924-9. PubMed ID: 21228384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of vitreolysis and vitreous detachment with hyaluronidase and perfluoropropane gas.
    Kang SW; Hyung SM; Choi MY; Lee J
    Korean J Ophthalmol; 1995 Dec; 9(2):69-78. PubMed ID: 8818320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of experimental proliferative vitreoretinopathy with daunomycin and triamcinolone based on the time course of the disease.
    Hui YN; Hu D
    Graefes Arch Clin Exp Ophthalmol; 1999 Jul; 237(7):601-5. PubMed ID: 10424311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.